Home > Insider Trading > Filing (0001209191-22-017318)

Filing Details

Accession Number:: 0001209191-22-017318
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-03-08 19:35:30
Reporting Period:: 2022-03-04

Accepted Time:: 2022-03-08 19:35:30
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1582313	Xenon Pharmaceuticals Inc.	XENE	Pharmaceutical Preparations (2834)	980661854

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619962	Sherrington Robin	200 - 3650 Gilmore Way Burnaby A1 V5G 4W8	Evp, Strategy & Innovation	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Shares	Acquisiton	2022-03-04	1,234	$3.67	33,466	No	4	M	Direct
Common Shares	Disposition	2022-03-04	696	$31.42	32,770	No	4	F	Direct
Common Shares	Acquisiton	2022-03-04	6,172	$3.67	38,942	No	4	M	Direct
Common Shares	Disposition	2022-03-04	6,710	$30.56	32,232	No	4	S	Direct
Common Shares	Disposition	2022-03-04	5,000	$30.15	27,232	No	4	S	Direct
Common Shares	Disposition	2022-03-04	5,000	$31.05	22,232	No	4	S	Direct
Common Shares	Disposition	2022-03-04	5,000	$30.23	17,232	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	F	Direct
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Shares	Stock Option (Right to Buy)	Disposition	2022-03-04	1,234	$0.00	1,234	$3.67
Common Shares	Stock Option (Right to Buy)	Disposition	2022-03-04	6,172	$0.00	6,172	$3.67

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		2022-03-10	No	4	M	Direct
0		2022-03-10	No	4	M	Direct

Footnotes

The exercise price was converted to U.S. dollars from $3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
Represents the closing price of the Company's common shares on March 3, 2022, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.10 to $31.17, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.78 to $31.07, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $30.15 to $30.33, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
1/3 of the shares subject to the Option vested on January 1, 2012 (the "First 2012 Vesting Commencement Date") and thereafter the remaining 2/3 of the shares subject to the Option vest each monthly anniversary of the First 2012 Vesting Commencement Date over the following 4 years.
Expiration date differs from originally reported date due to an automatic extension provided by the option plan as a result of the original expiration date falling during a Company blackout period.
25% of the shares subject to the Option vested on the one year anniversary of January 1, 2012 (the "Second 2012 Vesting Commencement Date") and thereafter 1/48th of the shares subject to the Option vest on each monthly anniversary of the Second 2012 Vesting Commencement Date